Misoprostol is a synthetic prostaglandin E₁ (PGE₁) analogue that is used clinically for a variety of gastrointestinal and obstetric‑gynecological indications. It is marketed under various trade names, including Cytotec, and is administered orally, vaginally, sublingually, or rectally depending on the therapeutic purpose.
Chemical and Pharmacological Profile
- IUPAC name: (±)-4‑(5‑hydroxy‑2‑propenyl)‑2‑[(hydroxy‑methyl)‑hydroxy]‑4‑oxabicyclo[3.1.0]hexane‑3‑carboxylic acid.
- Molecular formula: C₂₂H₃₈O₅
- Molar mass: 384.5 g·mol⁻¹
- Mechanism of action: Misoprostol binds to prostaglandin receptors (primarily EP₂ and EP₃) on smooth muscle and mucosal cells, leading to increased cyclic AMP levels. In the gastrointestinal tract, it stimulates mucus and bicarbonate secretion and enhances gastric mucosal blood flow, thereby exerting a protective effect against acid‑related injury. In the reproductive system, it induces uterine contractions and cervical softening by promoting the release of endogenous prostaglandins.
Medical Uses
| Indication | Route & Typical Dosage | Therapeutic Rationale |
|---|---|---|
| Prevention of NSAID‑induced gastric ulcers | Oral, 200 µg daily (commonly 100 µg twice daily) | Augments mucosal defenses against acid erosion |
| Induction of labor (post‑term pregnancy) | Vaginal or oral, 25‑50 µg every 4–6 h | Stimulates uterine contractility |
| Medical termination of early pregnancy (≤ 10 weeks gestation) | Combined with mifepristone (or alone in some protocols): 200 µg orally, followed 24–48 h later by 800 µg vaginally | Achieves uterine evacuation through sustained contractions |
| Treatment of postpartum hemorrhage (PPH) | Sublingual or vaginal, 800‑1 000 µg single dose | Promotes uterine tone to reduce bleeding |
| Cervical ripening before surgical procedures | Vaginal, 25‑50 µg every 6 h for up to 24 h | Facilitates cervical dilation |
Adverse Effects
Common side effects include abdominal cramping, diarrhea, nausea, vomiting, and headache. Uterine hyperstimulation and abnormal bleeding are notable when used in obstetric contexts. Contraindications encompass known hypersensitivity to prostaglandins, previous cesarean section or uterine surgery (for certain obstetric uses), and established intrauterine infection.
Regulatory and Legal Status
Misoprostol is approved by the U.S. Food and Drug Administration (FDA) for gastric ulcer prophylaxis in patients receiving chronic non‑steroidal anti‑inflammatory drugs (NSAIDs). Its use for obstetric indications is considered off‑label in many jurisdictions, though it is incorporated into national guidelines for medical abortion, labor induction, and postpartum hemorrhage in numerous countries. Regulatory control varies; some nations classify it as a prescription‑only medication, while others impose restrictions due to its abortifacient properties.
History
Developed in the 1970s by the Swedish pharmaceutical company Sandoz (now part of Novartis), misoprostol was initially introduced for ulcer prevention. Its potent uterotonic effects were identified shortly thereafter, leading to expanded clinical research in the 1980s and 1990s on reproductive health applications. The World Health Organization (WHO) subsequently endorsed misoprostol for safe abortion and PPH management in resource‑limited settings.
Pharmacokinetics
- Absorption: Rapidly absorbed after oral, vaginal, or sublingual administration; bioavailability ≈ 70 % (oral).
- Distribution: Widely distributed; protein binding ≈ 98 %.
- Metabolism: Primarily hydrolyzed to the inactive metabolite misoprostol‑acid by hepatic and plasma esterases.
- Elimination: Renal excretion of metabolites; half‑life ≈ 20–40 minutes.
Societal and Public Health Impact
Misoprostol's stability at room temperature, low cost, and multiple routes of administration have made it a cornerstone of global reproductive health programs, particularly in low‑resource environments where access to surgical services is limited. Its inclusion on the WHO Model List of Essential Medicines reflects its importance for both gastroprotective therapy and reproductive health interventions.